GlycoSyn strikes $14 million deal with Ginkgo Bioworks to broaden the reach of its human milk oligosaccharides (HMOs) platform

Published:
November 8, 2018
Coverage:
Accelerating Materials Innovation More...
Categories:
Prebiotics | Synthetic biology
Activities:
Investment More...
10085 thumb square
by Thomas Hayes
Very important

Just two months ago, we predicted that HMOs would be a high-growth area for prebiotics, and this event certainly supports that. After obtaining EU regulatory approval for production of 2'-fucosyllactose (2'-FL) in partnership with FrieslandCampinaGlycoSyn is looking to use this deal with Ginkgo Bioworks to lead the race against Jennewein Biotechnologie and DuPont/Inbiose to produce HMOs beyond 2'-FL. From Ginkgo's perspective, this adds a new twist to its business model – providing direct investment and foundry access to smaller companies. Assuming Ginkgo will continue doing this, clients should seek out Ginkgo as a resource to help optimize strain design for fermentation products of interest from startups and SMEs.

For the original news article, click here .


Further Reading

Cathay invests additional $500 million to expand production of its bio-based pentamethylene diamine (DN5) and long-chain diacids (LCDAs)

News Commentary | December 11, 2018

After completing the initial phase of its Wusu plant in 2018, Cathay is making yet another substantial investment in the same facility supported by the government of the city of Wusu. This represents a major step toward its goals to increase its LCDA capacity to 100 ktpa and its DN5 capacity to 500 ... Not part of subscription

BBMC 2018 Year in Review

Analyst Insight | December 6, 2018

2018 was rife with events within the bio‑based and overall sustainable materials and chemicals space as startups, large companies, and governments announced new products and partnerships, as well as sustainability strategies and policies. Here, we present some of the major events in order to ... Not part of subscription

Zymergen raises $400 million Series C

News Commentary | December 13, 2018

Zymergen had previously focused on improving its clients' strains – claiming scales over 100,000 tpa for strains and producing on the order of $100 million worth of product per year. Not only will Zymergen use this funding to double the capacity of its platform, but it also intends to use the ... To read more, click here.